Skip to main content
Equibles

Phillip Chan

CEO

Cytosorbents Corp (CTSO)

Board Member

Cytosorbents Corp (CTSO)

Equibles does not estimate personal net worth.

Get an email with a short summary when Cytosorbents Corp publishes a filing, an earnings call transcript or a press release.

Get CTSO alerts

About Phillip Chan

Phillip Chan is recorded as Board Member at Cytosorbents Corp (CTSO) since January 1, 2008 and CEO at Cytosorbents Corp (CTSO). The newest filing on record that lists Phillip Chan as CEO and Board Member at Cytosorbents Corp (CTSO) is dated June 25, 2026. The proxy statement of Cytosorbents Corp reports total compensation of $808,431 for Phillip Chan in fiscal 2025, including a base salary of $502,165. Disclosed compensation is on record for 8 fiscal years. Phillip Chan has spoken on 23 earnings calls across 1 company, most recently for Cytosorbents Corp on August 6, 2026. Cytosorbents Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Cytosorbents Corp includes Alexander D'Amico (CFO), Kathleen Bloch (CFO), Peter J. Mariani (CFO) and 7 others.

Phillip Chan on recent calls

“Turning to our operational update, when I think about the second quarter, one word comes to mine progress. While we recognize that our share price continues to reflect skepticism regarding our ability to execute, we believe the company today is materially stronger than it was just one year ago.”
CEO, Cytosorbents Corp Q2 FY2026 Earnings Call ·
“Before I start, I'd like to remind everyone of the current regulatory status of our products.”
CEO, Cytosorbents Corp Q1 FY2026 Earnings Call ·
“CytoSorbents continues to make solid progress as we execute on our long-term growth strategy. Our company is built around a platform blood purification technology designed to remove harmful substances and toxins from the bloodstream.”
CEO, Cytosorbents Corp Q3 FY2025 Earnings Call ·
“Thank you very much, Adanna, and good afternoon, and welcome, everyone, to our second quarter 2025 earnings call.”
CEO, Cytosorbents Corp Q2 FY2025 Earnings Call ·
“As a quick summary for those who are new to the company, CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit in cardiac surgery through blood purification and the removal of harmful substances from blood with our proprietary sorbent bead technology.”
CEO, Cytosorbents Corp Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Cytosorbents Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Cytosorbents Corp (CTSO) $502,165 $808,431
2024 Cytosorbents Corp (CTSO) $359,352 $899,695
2023 Cytosorbents Corp (CTSO) $482,851 $1,333,402
2021 Cytosorbents Corp (CTSO) $482,851 $1,790,596
2020 Cytosorbents Corp (CTSO) $455,520 $1,388,190
2019 Cytosorbents Corp (CTSO) $438,000 $1,404,376
2018 Cytosorbents Corp (CTSO) $400,000 $1,247,295
2017 Cytosorbents Corp (CTSO) $378,000 $827,597

Recent activity

Show 11 earlier activities